NEGIRI protokol - DBCG

21 Referencer
Baggrund vedr. brystkræft
Bajetta E, Procopio G, Celio L et al. Safty and efficacy of two different doses of
Capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol
2005; 23: 2155-61.
En fase II-undersøgelse af irinotecan ugentligt til patienter med lokal avanceret eller metastatiskHER 2
negativ brystkræft og øget antal kopier af topoisomerase 1(TOP1) genet.
Protokol version 16. maj 2013, amendment nr. 2
Forsøget er godkendt af Lægemiddelstyrelsen Eudract nr.: 2012-002348-26 og
Den Videnskabsetiske Komite, nr.: H-1-2012-066
39
Black RJ, Bray F, Ferlay J, Parkin DM. Cancer incidence and mortality in the European
Union: Cancer registry data and estimates of National incidence. Eur J Cancer 1997; 33:
1075-107.
Brewster AM, Hortobagyl GN, Broglio KR et al. Residual risk of breast cancer Recurrence
5 years after adjuvant therapy. J Natl Cancer Inst. 2008; 100: 1179-83.
Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic
breast cancer. Oncologisk 2006; 11: 325-335.
Oshaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of
oral capacitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide,
methotrexate and 5-flourouracil) as first-line therapy for Advanced/metastatic breast
cancer. Ann Oncol 2001; 12: 1247-54.
Overmoyer B. Options for the treatment of patients with taxane-refractory Metastatic
breast cancer. Clin Breast Cancer 2008; 8 (Suppl 2): S61-S70.
Smigal C. Jemal A. Ward E et al. Trends in breast cancer by race and ethnicity: Update
2006. CA Cancer J Clin 2006; 56: 168-83.
Solomayer EF, Diel IJ, Meyberg GC et al. Metastatic breast cancer: clinical course,
prognosis and therapy related to the first site of metastasis. Breast Cancer Research
Treat 2000; 59: 271-8.
Wilcken N, Dear R, Chemotherapy in metastatic breast cancer: A summery of all
randomised trials reported 2000 – 2007. Eur J Cancer 2008; 44:2218-25.
Irinotecan
Gilbert DC, Chalmers AJ, El-Khamisy SF. Topoisomerase I inhibition in colorectal cancer:
biomarkers and therapeutic targets. Br J Cancer 2011 Nov 22. doi: 10.1038/bjc.2011.498.
[Epub ahead of print]
Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic
colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343: 905-14.